男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Bayer's $60m investment to boost capacity, reaffirm its commitment to China

chinadaily.com.cn | Updated: 2020-08-28 16:51
Share
Share - WeChat
Bayer today announces to launch the capacity expansion project of its Pharmaceuticals Product Supply Beijing site for addressing further demand of its drug products in China. [Photo provided to chinadaily.com.cn]

Bayer today announces to launch the capacity expansion project of its Pharmaceuticals Product Supply Beijing site for addressing further demand of its drug products in China. With an investment of more than 50 million euros ($59.52 million), the planned project is designated to increase the production capacity and accelerate the implementation of innovative digital solutions at the Beijing site, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. Representatives from China's Ministry of Commerce, Germany Embassy, Beijing Municipal Government and the Beijing Economic-Technological Development Area attended the ceremony.

"We are very pleased to see that this project marks the latest milestone of Bayer's development journey in China, which is also a new start for us to consistently deliver our high-quality products and benefit more Chinese patients in need," said Wei Jiang, executive vice-president and president of Bayer Pharmaceuticals Region China & APAC and president of Bayer Group Greater China. "In the face of huge challenges caused by the COVID-19 pandemic, the initiative fully demonstrates Bayer's unswerving confidence and commitment to China, and again shows our aspiration of serving more Chinese patients and determination to contribute to building a healthy China."

The new production lines are expected to become operational at the end of 2022. Then the estimated annual output of the Beijing Site can be increased by about 40 percent, which will again reinforce its position among the most advanced production sites of Bayer Pharmaceuticals' global network.

Cardiovascular diseases and diabetes remain among major chronic diseases which are prioritized by the Chinese central government in its Healthy China Action Plan in efforts to address major health challenges caused by the prevalence of chronic diseases. In addition, the COVID-19 pandemic reinforces the significance of a reliable, resilient drug supply chain to the country's public health as well as well-beings of Chinese people.

The expansion project covers production area and related technical area, which is designed as a world-class manufacturing facility. It includes new high-speed production lines in combination with a sophisticated logistics system.

Bayer today announces to launch the capacity expansion project of its Pharmaceuticals Product Supply Beijing site for addressing further demand of its drug products in China. [Photo provided to chinadaily.com.cn]
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 洪泽县| 娄底市| 花莲县| 安龙县| 新巴尔虎左旗| 宁明县| 友谊县| 团风县| 和田县| 西宁市| 健康| 潮州市| 安福县| 邵阳县| 大埔县| 密山市| 株洲市| 象州县| 普陀区| 安化县| 博白县| 北辰区| 民勤县| 南宫市| 图木舒克市| 合江县| 巧家县| 长宁县| 荆门市| 崇礼县| 六枝特区| 东兴市| 桦南县| 贺兰县| 黄龙县| 丰城市| 罗甸县| 凤山县| 抚松县| 宜章县| 平阳县|